Gantenerumab
Fab fragment of gantenerumab (blue) encircling and binding an Aβ(1–11) fibril (bright green). PDB: 5CSZ. | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Beta-amyloid (Aβ40/42) |
| Clinical data | |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6496H10072N1740O2024S42 |
| Molar mass | 146276.71 g·mol−1 |
| (what is this?) (verify) | |
Gantenerumab is a monoclonal antibody for the treatment of Alzheimer's disease being developed by Hoffmann-La Roche pharmaceuticals.
Gantenerumab binds to and clears aggregated beta amyloid fibers.
A phase III clinical trial of gantenerumab was stopped early because of a lack of efficacy. Gantenerumab was also evaluated in younger patients at high risk of developing Alzheimer's disease but after five years of treatment, the drug did little to slow cognitive decline in patients.
A study published in 2025 suggests that Gantenerumab appears to reduce the risk of Alzheimer's-related dementia in people with rare genetic mutations mutations that cause the overproduction of amyloid in the brain. These people are normally destined to develop the disease in their 30s, 40s or 50s.